

NAME OF THE MEDICINAL PRODUCT

Ringer's Solution for Infusion

COMPOSITION

1000 ml of solution for infusion contain:

Sodium chloride	8.60 g
Potassium chloride	0.30 g
Calcium chloride dihydrate	0.33 g

Electrolyte concentrations:

Sodium	147 mmol/l
Potassium	4.0 mmol/l
Calcium	2.2 mmol/l
Chloride	156 mmol/l

Excipient: Water for injection.

THERAPEUTIC INDICATIONS

Fluid and electrolyte substitution in the condition of hypochloremic alkalosis, chloride losses, isotonic or hypotonic dehydration, short-term intravascular volume replacement, vehicle solution for compatible electrolyte concentrates and medicinal products.

CONTRAINDICATIONS

Ringer's Solution for Infusion must not be administered in states of hyperhydration.

UNDESIRABLE EFFECTS

Undesirable effects are listed according to their frequencies as follows:

Rare: ($\geq 1/10\ 000$ to $< 1/1000$)

Metabolism and nutrition disorders

Administration may cause hyperchloremia.

Rare: Adverse reactions may be associated with the technique of administration including febrile response, infection at the site of injection, local pain or reaction, vein irritation, venous thrombosis or phlebitis extending from the site of injection and extravasation.

Adverse reactions may be associated with the medications added to the solution; the nature of the additive will determine the likelihood of any other undesirable effects.

WARNINGS

Keep out of the sight and reach of children. For single use only. Discard unused contents. Do not reconnect partially used containers. Use only if solution is clear and container and closure are undamaged.

NOTE

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information.

B. Braun Melsungen AG, 34209 Melsungen, Germany, 07/2014

Title: Ringer Solution for Infusion Initiator: Roxana ? Tranca

This document is signed electronically in compliance with the B. Braun electronic signature policies and procedures by following persons:

UserName: Pfleging, Petra (pflepede)

Title: HC-RA-DE08 Manager Global Regulatory Affairs Pharmaceuticals

Date: Thursday, 29 November 2018, 12:11 W. Europe Daylight Time

Meaning: Document signed as Author

UserName: Elsing, Andreas (elsiande)

Title: HC-ME-DE08C Manager Scientific Affairs

Date: Friday, 30 November 2018, 09:14 W. Europe Daylight Time

Meaning: Approve Document
